Our portfolio company Eternygen GmbH will be present at Bio-Equity Europe in Barcelona from 19th to 21st of May at Crowne Plaza in Barcelona. Eternygen will be represented by its Head of Research Dr. Girt Zahn and by its board member Dr. Klaus Schollmeier. The team looks forward to meeting investors and potential cooperation partners to drive their scientific process forward. Feel free to get in touch with us, if you would like to schedule a meeting!
ABOUT ETERNYGEN GMBH
Eternygen is a Berlin, Germany based Biotech Company founded in June 2012 to focus on the research, development and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The founding team consists of renowned scientists from leading German universities and academic institutes as well as serial entrepreneurs from the venture and industry community. Eternygen is a virtual company supported by a network of senior industry experts and contract research organizations. Eternygen shareholders include Epidarex Capital, Evotec AG, VC Fonds Technologie, Berlin, Germany managed by IBB Beteiligungsgesellschaft mbH, and two renowned family offices. For additional information please go to www.eternygen.com.